Apremilast for treating moderate to severe plaque psoriasis in children and young people

Apremilast is being investigated for the treatment of moderate to severe plaque psoriasis in children and adolescents (aged 6 to 17 years old). Psoriasis is a skin disease that causes a rash with itchy, scaly patches, most commonly on the knees, elbows, trunk, and scalp. Plaque psoriasis is the most common, and is characterised by epidermal thickening and scaling, usually affecting external surfaces and the scalp. The plaques can be itchy or sore, or both. In severe cases, the skin around your joints may crack and bleed. Common psoriasis triggers include injuries such as cuts, abrasions or sunburn, obesity, smoking and excessive alcohol. Psoriasis poses a significant economic burden because lifelong care is often required. In addition to physical pain, psoriasis causes social and psychological burden: social exclusion, discrimination, and stigma can be devastating for patients, who suffer from burdensome depression. Long-term use of currently available therapies is often compromised by side effects, loss of effectiveness over time, and administration by injection.